Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00558051 · ClinicalTrials.gov registry record · Phase 1
Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer
A Phase 1 study, sponsored by Pawel Kalinski.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00558051 is a Phase 1 study that has completed, run by Pawel Kalinski. The registered enrollment target is 15 participants.
The verdict
NCT00558051, a Phase 1 study, has completed, sponsored by Pawel Kalinski.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the administration, safety and immunologic effectiveness of an experimental vaccine for colorectal cancer patients.
Interventions
- BIOLOGICAL DC-based vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-01 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00558051
The ClinicalTrials.gov registry entry for NCT00558051 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pawel Kalinski, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DC-based vaccine is the first listed.
NCT00558051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00558051 about?
NCT00558051 is a clinical study titled "Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer". The purpose of this study is to evaluate the administration, safety and immunologic effectiveness of an experimental vaccine for colorectal cancer patients.
What is the current status of trial NCT00558051?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2008-01. Estimated completion is 2014-04.
What interventions are being tested in trial NCT00558051?
The interventions under investigation include: DC-based vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00558051?
This trial is sponsored by Pawel Kalinski, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.